Divergent safety profiles of TNF inhibitors in pregnancy: a comprehensive pharmacovigilance analysis of the FAERS database [0.03%]
肿瘤坏死因子抑制剂妊娠期安全性分析：FAERS数据库药物警戒综合分析
Zijun Yan,Haitao Chen,Jiaqi Sun et al.
Zijun Yan et al.
Objectives: While tumor necrosis factor inhibitors (TNFis) are widely used in pregnancy, assumption of a uniform class-wide safety profile warrants scrutiny. This pharmacovigilance study aimed to explore potential heterog...
TCR recognition of peptide-HLA class II complexes in autoimmunity: Structural insights for therapeutic targeting [0.03%]
自身免疫中TCR识别肽-HLA-II复合物的结构见解：治疗靶向的潜在应用
Zhanrong Cui,Joshua D Ooi,Yi-Tian Ting
Zhanrong Cui
Autoimmune diseases encompass a broad spectrum of disorders in which self-reactive T and B cells breach immune tolerance and drive chronic tissue inflammation. Although broad immunosuppressants and cytokine-targeted biologic therapies have ...
Interlaboratory variability in laboratory testing and reporting of myositis autoantibodies [0.03%]
肌炎自身抗体实验室检测与报告的室间差异性分析研究
Georgina R Harvey,Idil Ashur,Xavier Bossuyt et al.
Georgina R Harvey et al.
Objectives: Myositis-specific and myositis-associated autoantibodies (MSA/MAA) are important biomarkers used in the diagnosis and assessment of patients with idiopathic inflammatory myopathies. To date, limited guidance e...
Perinatal use of targeted synthetic DMARDs and maternal-neonatal outcomes in autoimmune disease: A population-based cohort study [0.03%]
靶向合成DMARDs在围产期的使用和自身免疫性疾病患者的母婴结局：一项基于人群的队列研究
Vienna Cheng,Eric C Sayre,Neda Amiri et al.
Vienna Cheng et al.
Objectives: While targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) have advanced autoimmune disease management, the paucity of perinatal safety data limits evidence-based decision-making in pregnancy. W...
Evaluation of non-invasive techniques for the diagnosis of pulmonary complications in systemic sclerosis and scleroderma-like overlap syndromes: role of lung ultrasound [0.03%]
评估无创技术在系统性硬化病和硬皮病重叠综合征肺并发症诊断中的价值：肺超声的作用
Mattia Perazzi,Eleonora Croce,Gabriele Macrì et al.
Mattia Perazzi et al.
Background and aim: Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are the leading cause of death in Systemic Sclerosis (SSc) and severely affect patients' quality of life. Early, accurate, and ...
Anti-MDA5 monoclonal antibodies from patients with dermatomyositis - B cell characteristics and differential targeting of the helicase domains [0.03%]
抗MDA5单克隆抗体的特性及不同靶向解旋酶结构域的自身免疫肌炎患者的B细胞特征
Eveline Van Gompel,Marina Galešić,Nicolas Delaroque et al.
Eveline Van Gompel et al.
Objectives: Autoantibodies targeting melanoma differentiation associated protein 5 (MDA5) are strongly associated with dermatomyositis (DM) and may contribute to its pathogenesis. Here we aimed to investigate MDA5+ B cell...
Multiple sclerosis-associated EBNA2 variants influence the response to peginterferon beta-1a therapy [0.03%]
与多发性硬化症相关的EBNA2变异体影响PEG干扰素β-1a治疗的反应
Caterina Veroni,Fortunata Carbone,Daniela Ricci et al.
Caterina Veroni et al.
Background: Strong evidence links Epstein-Barr virus (EBV) infection to Multiple Sclerosis (MS). Peginterferon beta-1a (peg-IFN), currently the most used interferon formulation among first-line treatments in MS, displays ...
Vascular effects of achieving low disease activity in axial spondyloarthritis - A 2-year prospective treat-to-target study [0.03%]
实现轴性脊柱关节炎低疾病活动度的血管效应-一项为期两年的治疗目标研究
Huan Meng,Sze-Lok Lau,Isaac T Cheng et al.
Huan Meng et al.
Objectives: To investigate the effect of achieving Axial Spondyloarthritis Disease Activity Score (ASDAS) low disease activity (LDA) on the progression of subclinical atherosclerosis and arterial stiffness in axial spondy...
What's in a name? - juxtaposing T follicular, peripheral and resident helper cells in B cell-driven autoimmune diseases [0.03%]
名称背后的意义——T滤泡、周围及驻留型辅助性T细胞在B细胞驱动的自身免疫疾病中的比较研究
Fabiënne van Puijfelik,Kirsten L Kuiper,Jasper Rip et al.
Fabiënne van Puijfelik et al.
Effective humoral immunity depends on tightly regulated interactions between B cells and CD4+ T-helper subsets across lymphoid and peripheral tissues. In autoimmune diseases, these regulatory checkpoints fail, enabling autoreactive B cells ...
Interventional studies targeting the prodromal or preclinical phase of immune-mediated disease to benefit patient outcomes: a scoping review [0.03%]
针对免疫介导性疾病前驱期或临床前期的干预研究以改善患者预后：综述性文章
Kara Moscovitz,Daivat Bhavsar,Helen Tremlett
Kara Moscovitz
Background: Immune-mediated diseases, including multiple sclerosis (MS), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and type 1 diabetes (T1D) often progress through prodromal or preclinical phases befo...